Publicaciones en colaboración con investigadores/as de University of Washington (154)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299

  5. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  6. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae

    American Journal of Transplantation, Vol. 23, Núm. 7, pp. 1022-1034

  7. Efficient multi-fidelity computation of blood coagulation under flow

    PLoS Computational Biology, Vol. 19, Núm. 10

  8. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

    Annals of Oncology, Vol. 34, Núm. 4, pp. 397-409

  9. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

  10. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  11. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  12. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 4, pp. 1081-1095

  13. Pulmonary vein flow split effects in patient-specific simulations of left atrial flow

    Computers in Biology and Medicine, Vol. 163

  14. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience

    Clinical Genitourinary Cancer, Vol. 21, Núm. 5, pp. 584-593

  15. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594

  16. Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK)

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1542-1552

  17. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222